|
|
| Line 147: |
Line 147: |
| In the clinical study ~20 fold increase bioavailability was measured compare to standard quercetin with equal doses. Given that Quercetin Phytosome contains ~40% and has a ~20 fold relative bioavailabilty, one can assume that the total bioavailability of standard quercetin is less than 2%. | | In the clinical study ~20 fold increase bioavailability was measured compare to standard quercetin with equal doses. Given that Quercetin Phytosome contains ~40% and has a ~20 fold relative bioavailabilty, one can assume that the total bioavailability of standard quercetin is less than 2%. |
|
| |
|
| ===Implications of Low Bioavailability===
| |
| The low bioavailability of quercetin raises questions about the clinical relevance of its potential health benefits observed in vitro and in animal studies. It necessitates the need for effective delivery systems and formulations to realize its therapeutic potential in humans. Additionally, understanding the biological activities of its metabolites is crucial, as they are the predominant forms present in systemic circulation.
| |
|
| |
| ===Mode of Action===
| |
| Quercetin exerts its effects predominantly through its antioxidant and anti-inflammatory properties. It can scavenge free radicals and reduce oxidative stress, modulate signaling pathways involved in inflammation, and inhibit the formation and release of pro-inflammatory mediators. It has also demonstrated the ability to modulate several cellular enzymes and receptors, thus influencing a variety of biological processes and potentially offering protection against a range of diseases.
| |
|
| |
|
|
| |
|
